DK2083863T3 - Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi - Google Patents

Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi

Info

Publication number: DK2083863T3
Authority: DK; Denmark
Prior art keywords: sourcopulmonal; dysplasy; babies; beta; risk
Prior art date: 2006-10-03

Application number

DK07867199.7T

Other languages

English (en)

Inventor

James B Streisand

Jesse D Roberts Jr

Original Assignee

Genzyme Corp

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-03

Filing date

2007-10-03

Publication date

2015-06-22

2007-10-03 Application filed by Genzyme Corp, Gen Hospital Corp filed Critical Genzyme Corp

2015-06-22 Application granted granted Critical

2015-06-22 Publication of DK2083863T3 publication Critical patent/DK2083863T3/da

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK07867199.7T 2006-10-03 2007-10-03 Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi DK2083863T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82793306P	2006-10-03	2006-10-03
PCT/US2007/021234 WO2008060371A1 (en)	2006-10-03	2007-10-03	USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA

Publications (1)

Publication Number	Publication Date
DK2083863T3 true DK2083863T3 (da)	2015-06-22

Family

ID=39217964

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15154393.1T DK2918288T3 (da)	2006-10-03	2007-10-03	Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
DK07867199.7T DK2083863T3 (da)	2006-10-03	2007-10-03	Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15154393.1T DK2918288T3 (da)	2006-10-03	2007-10-03	Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi

Country Status (10)

Country	Link
US (3)	US8642034B2 (da)
EP (3)	EP2918288B1 (da)
CN (2)	CN101553254A (da)
DK (2)	DK2918288T3 (da)
ES (2)	ES2538265T3 (da)
HU (1)	HUE035575T2 (da)
IL (2)	IL197797A (da)
MX (1)	MX2009003518A (da)
PL (2)	PL2918288T3 (da)
WO (1)	WO2008060371A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012061811A2 (en) *	2010-11-05	2012-05-10	Fibrogen, Inc.	Treatment method for lung remodeling diseases
US9797903B2 (en)	2012-10-24	2017-10-24	Winthrop-University Hospital	Non-invasive biomarker to identify subject at risk of preterm delivery
AR095240A1 (es)	2013-03-11	2015-09-30	Genzyme Corp	ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS
CA2911514A1 (en)	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
CN116655801A (zh)	2013-08-22	2023-08-29	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
JP7320350B2 (ja)	2015-08-04	2023-08-03	アクセルロンファーマインコーポレイテッド	骨髄増殖性障害を処置するための方法
WO2017044302A1 (en) *	2015-09-09	2017-03-16	Rush University Medical Center	Compositions and methods for treating bone diseases
GB201610044D0 (en) *	2016-06-08	2016-07-20	Ucb Biopharma Sprl	Antibodies
CN110785431B (zh)	2017-05-04	2024-05-07	阿塞勒隆制药公司	TGF-β受体II型融合蛋白及其用途
SG11202002065VA (en)	2017-09-13	2020-04-29	Progenity Inc	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS606629A (ja)	1983-06-23	1985-01-14	Sumitomo Chem Co Ltd	ホルムアルデヒドの製造法
US5262319A (en)	1985-04-19	1993-11-16	Oncogene Science, Inc.	Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5654270A (en)	1988-06-28	1997-08-05	La Jolla Cancer Research Foundation	Use of fibromodulin to prevent or reduce dermal scarring
AU633011B2 (en)	1988-06-28	1993-01-21	La Jolla Cancer Research Foundation	Suppression of cell proliferation by decorin
US5705609A (en)	1988-06-28	1998-01-06	La Jolla Cancer Research Foundation	Decorin fragments inhibiting cell regulatory factors
US5583103A (en)	1988-06-28	1996-12-10	La Jolla Cancer Research Foundation	Inhibition of transforming growth factor beta activity
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (ja)	1989-09-29	1995-08-30	ラホヤキャンサーリサーチファウンデーション	細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
JPH05503003A (ja)	1989-11-22	1993-05-27	ジェネンテク，インコーポレイテッド	潜在性関与ペプチドおよびその使用
WO1991010727A1 (en)	1990-01-22	1991-07-25	La Jolla Cancer Research Foundation	Inhibitors of cell regulatory factors
FR2677038B1 (fr) *	1991-06-03	1994-08-12	Bel Fromageries	Additif alimentaire pour l'alimentation humaine et animale et aliments le contenant.
US6008011A (en)	1991-10-31	1999-12-28	Whitehead Institute For Biomedical Research	TGF-β type II receptor cDNAs
CA2122491A1 (en)	1991-10-31	1993-05-13	Herbert Y. Lin	Tgf-.beta. type receptor cdnas and uses therefor
WO1993009800A1 (en)	1991-11-14	1993-05-27	La Jolla Cancer Research Foundation	Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en)	1992-03-17	1992-04-29	British Tech Group	Treatment of fibrotic disorders
US5869462A (en)	1992-09-10	1999-02-09	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en)	1992-09-10	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of proliferation of vascular smooth muscle cell
WO1994009812A1 (en)	1992-10-26	1994-05-11	Kirin Brewery Company, Limited	METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
JPH08504763A (ja)	1992-10-29	1996-05-21	セルトリックスファーマシューティカルズ，インコーポレイテッド	治療薬としてのＴＧＦ−βレセプターフラグメントの使用
AU5541094A (en)	1992-10-30	1994-05-24	Consejo Superior De Investigaciones Cientificas	Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en)	1992-10-30	1998-11-03	Hsc Research & Development Limited Partnership	Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE211762T1 (de)	1993-04-30	2002-01-15	Biognostik Ges	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0737071A1 (en)	1993-06-15	1996-10-16	Il- Yang Pharm. Co., Ltd.	Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
WO1995010610A1 (en)	1993-10-15	1995-04-20	La Jolla Cancer Research Foundation	BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
AU2404695A (en)	1994-05-04	1995-11-29	Mount Sinai Hospital Corporation	Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5772995A (en)	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en)	1994-08-25	1996-02-26	Kenichi Matsunaga	Binding agent for growth factor
JPH08119984A (ja)	1994-08-31	1996-05-14	Nkk Corp	ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en)	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
AU2749697A (en)	1996-04-30	1997-11-19	Genzyme Corporation	Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja)	1996-06-19	1998-03-10	Advanced Sukin Res Kenkyusho:Kk	細胞外マトリツクスの異常蓄積抑制剤
ES2253788T3 (es)	1996-10-25	2006-06-01	Ethicon, Inc.	Ensayo de agente anti-fibrotico.
DE69838061T2 (de)	1997-04-18	2008-03-13	Biogen Idec Ma Inc., Cambridge	Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
US7779020B2 (en)	2002-03-01	2010-08-17	International Business Machines Corporation	Small-footprint applicative query interpreter method, system and program product
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
WO2000047102A2 (en) *	1999-02-11	2000-08-17	The General Hospital Corporation	COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
KR100425525B1 (ko)	2000-11-21	2004-03-30	재단법인서울대학교산학협력재단	조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
AU3956002A (en)	2000-11-28	2002-06-11	Childrens Medical Center	Determination of risk and treatment of complications of prematurity
EP1363904A1 (en)	2001-02-02	2003-11-26	Glaxo Group Limited	Pyrazoles as tgf inhibitors
GB0102673D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102668D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
DE60203263T2 (de)	2001-02-02	2006-02-09	Smithkline Beecham Corp.	Pyrazolderivate gegen tgf überexprimierung
GB0102672D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102665D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
EP1397364B1 (en)	2001-05-24	2007-07-25	Eli Lilly And Company	Novel pyrrole derivatives as pharmaceutical agents
WO2003061587A2 (en)	2002-01-22	2003-07-31	Genzyme Corporation	USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
AR039241A1 (es)	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1506191A1 (en)	2002-05-15	2005-02-16	Smithkline Beecham Corporation	Benzoxazine and benzoxazinone substituted triazoles
WO2003097615A1 (en)	2002-05-17	2003-11-27	Scios, Inc.	TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
AU2003256783A1 (en)	2002-07-25	2004-02-16	Scios, Inc.	METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
GB0217786D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Compounds
UA80295C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
UA80296C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Imidazolopyridines and methods of making and using the same
EP1549316A4 (en)	2002-09-10	2008-04-09	Scios Inc	HAMMER OF TFGbeta
ES2291664T3 (es)	2002-09-17	2008-03-01	Eli Lilly And Company	Derivados de pirazolopiridina como inhibidores de la transduccion de señales de tgf beta para el tratamiento del cancer.
AU2003268155A1 (en)	2002-09-19	2004-04-08	Eli Lilly And Company	Methods of inhibiting tgf beta with substituted pyrazoles
AU2003291642A1 (en)	2002-11-22	2004-06-18	Eli Lilly And Company	Pyrazoloazepine compounds as pharmaceutical agents
UA80571C2 (en)	2002-11-22	2007-10-10	Lilly Co Eli	Quinolinyl-pyrrolopyrazoles
AU2003291149A1 (en)	2002-11-22	2004-06-18	Scios, Inc.	USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
EP1572208A4 (en)	2002-11-22	2007-08-29	Scios Inc	METHOD FOR CONTROLLING PATHOLOGICAL CHANGE IN THE BETA-ADRENERGIC PATHWAY
EP1567527A1 (en)	2002-11-27	2005-08-31	Eli Lilly And Company	Condensed pyrazolo derivatives
AU2003297460A1 (en)	2002-12-19	2004-07-14	Scios, Inc.	TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS
ATE553378T1 (de)	2003-02-06	2012-04-15	Hologic Inc	Screening und behandlungsverfahren zur vorbeugung von frühgeburten
CL2004000234A1 (es)	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7223766B2 (en)	2003-03-28	2007-05-29	Scios, Inc.	Bi-cyclic pyrimidine inhibitors of TGFβ
WO2005010049A2 (en) *	2003-07-09	2005-02-03	Eli Lilly And Company	Tgf-beta1 ligands
WO2005032481A2 (en)	2003-09-30	2005-04-14	Scios Inc.	Quinazoline derivatives as medicaments
EP1708712A1 (en)	2003-12-24	2006-10-11	Scios, Inc.	Treatment of malignant gliomas with tgf-beta inhibitors
US7368445B2 (en)	2004-03-01	2008-05-06	Eli Lilly And Company	Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
BRPI0508761A (pt) *	2004-03-31	2007-08-14	Genentech Inc	anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
DE102004019253A1 (de)	2004-04-16	2005-11-10	Codewrights Gmbh	Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
MX2007001589A (es) *	2004-08-09	2007-08-02	Alios Biopharma Inc	Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
AU2005280168A1 (en)	2004-08-31	2006-03-09	Biogen Idec Ma Inc.	Pyrimidinylimidazoles as TGF-beta inhibitors
EP1786803A1 (en)	2004-08-31	2007-05-23	Biogen Idec MA, Inc.	Pyrimidinylpyrazoles as tgf-beta inhibitors
US7511056B2 (en)	2004-11-10	2009-03-31	Eli Lilly And Company	TGF-β inhibitors
US7723486B2 (en)	2005-02-08	2010-05-25	Optein, Inc.	Antibodies to TGF-β

2007
- 2007-10-03 DK DK15154393.1T patent/DK2918288T3/da active
- 2007-10-03 EP EP15154393.1A patent/EP2918288B1/en active Active
- 2007-10-03 PL PL15154393T patent/PL2918288T3/pl unknown
- 2007-10-03 MX MX2009003518A patent/MX2009003518A/es active IP Right Grant
- 2007-10-03 ES ES07867199.7T patent/ES2538265T3/es active Active
- 2007-10-03 DK DK07867199.7T patent/DK2083863T3/da active
- 2007-10-03 PL PL07867199T patent/PL2083863T3/pl unknown
- 2007-10-03 EP EP17181294.4A patent/EP3254696A1/en not_active Withdrawn
- 2007-10-03 CN CNA2007800447494A patent/CN101553254A/zh active Pending
- 2007-10-03 HU HUE15154393A patent/HUE035575T2/en unknown
- 2007-10-03 US US12/444,059 patent/US8642034B2/en active Active
- 2007-10-03 CN CN201510002215.1A patent/CN104645328A/zh active Pending
- 2007-10-03 EP EP07867199.7A patent/EP2083863B1/en not_active Not-in-force
- 2007-10-03 ES ES15154393.1T patent/ES2647472T3/es active Active
- 2007-10-03 WO PCT/US2007/021234 patent/WO2008060371A1/en active Application Filing
2009
- 2009-03-25 IL IL197797A patent/IL197797A/en active IP Right Grant
2013
- 2013-12-23 US US14/139,332 patent/US20140199399A1/en not_active Abandoned
2016
- 2016-11-28 US US15/362,392 patent/US20170233464A1/en not_active Abandoned
2017
- 2017-04-27 IL IL251994A patent/IL251994B/en active IP Right Grant

Also Published As

Publication number	Publication date
EP2083863A1 (en)	2009-08-05
IL251994B (en)	2021-01-31
CN104645328A (zh)	2015-05-27
US20100008911A1 (en)	2010-01-14
WO2008060371A1 (en)	2008-05-22
EP2918288B1 (en)	2017-08-16
PL2918288T3 (pl)	2018-02-28
US8642034B2 (en)	2014-02-04
HUE035575T2 (en)	2018-05-28
CN101553254A (zh)	2009-10-07
US20140199399A1 (en)	2014-07-17
ES2538265T3 (es)	2015-06-18
EP2083863B1 (en)	2015-03-18
EP2918288A1 (en)	2015-09-16
PL2083863T3 (pl)	2015-08-31
US20170233464A1 (en)	2017-08-17
IL251994A0 (en)	2017-06-29
DK2918288T3 (da)	2017-11-27
MX2009003518A (es)	2009-08-25
ES2647472T3 (es)	2017-12-21
EP3254696A1 (en)	2017-12-13
IL197797A (en)	2017-05-29
WO2008060371A8 (en)	2008-07-10
IL197797A0 (en)	2011-08-01

Publication	Publication Date	Title
DK2083863T3 (da)	2015-06-22	Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
DK2068889T3 (da)	2020-02-03	Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
DK2100614T3 (da)	2013-10-28	Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
EP2248496A4 (en)	2011-03-16	VOIDABLE ARTICLE
LTC2152290I2 (lt)	2018-12-27	Anti-il-5 antikūnų skyrimo būdai
DK2068874T3 (da)	2015-04-27	Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
EP2034073A4 (en)	2011-05-25	VOIDABLE ARTICLE
EP2079489A4 (en)	2013-01-02	ABSORBENT ARTICLE WITH ABSORPTION STRUCTURE
BRPI0819073A2 (pt)	2018-10-23	fralda descartável
EP2500003A4 (en)	2016-06-29	VOIDABLE ARTICLE
DK2300560T3 (da)	2014-05-19	Termisk behandling af biomasse
DK2139987T3 (da)	2013-09-02	Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK3017829T3 (da)	2020-03-02	Behandling af PRDC hos svin
EP2299957A4 (en)	2012-08-01	POCKET BAGS IN POURABLE ARTICLES
DK3399667T3 (da)	2020-03-09	Forhindring af selvinduceret interferens i anordning med dobbelt radio
EP2111835A4 (en)	2012-10-31	VOIDABLE ARTICLE
DK2231091T3 (da)	2013-01-28	Absorber og absorberende engangsartikel
DK2034830T3 (da)	2014-10-27	Anti-vla-1-antistof til behandling af slagtilfælde
EP2415437A4 (en)	2013-05-15	VOIDABLE ARTICLE
DK2470202T3 (da)	2014-01-27	Clostridium-neurotoksiner til anvendelse i behandling af præmatur ejakulation
DK1849445T3 (da)	2011-03-21	Absorberende engangsartikel og fremgangsmåde til fremstilling af samme
EP2478881A4 (en)	2013-11-06	VOIDABLE ARTICLE
BRPI0819071A2 (pt)	2018-10-23	fralda descartável
DK2342346T3 (da)	2013-11-04	Thermotoga til behandling af biomasse
EP2365947A4 (en)	2014-04-30	TREATMENT OF FLYBAG FOR USE IN CONCRETE